Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000811 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 690
- Enrollment target
NCT00000811: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000811 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 690 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (419% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000811, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 690 participants
- Enrollment target
Study Summary
This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin plus atovaquone) will be compared to sulfamethoxazole-trimethoprim (SMX/TMP) alone. This study also evaluates the long-term safety and tolerance of these different drugs. SMX/TMP is a commonly prescribed drug for the prevention of bacterial infections. However, the combination of azithromycin and atovaquone may be safer and more effective than SMX/TMP. This study compares the 2 treatments.
Interventions
- DRUG Azithromycin
- DRUG Atovaquone
- DRUG Sulfamethoxazole-Trimethoprim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 690 participants |
| Est. Completion | 2001-11 |
| Phase | Phase 2 |
What the finished NCT00000811 record still lists
NCT00000811 is an interventional study that assigns participants to a tested intervention. The registered 690 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (419% higher).
The record links to 0 conditions, and to 3 interventions - of which Azithromycin is the first listed.
NCT00000811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000811 about?
NCT00000811 is a clinical study titled "A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children". This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin plus atovaquone) will be compared to sulfamethoxazole-trimethoprim (SMX/TMP) alone. This study also evaluates the ...
What is the current status of trial NCT00000811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 690 participants. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00000811?
The interventions under investigation include: Azithromycin (DRUG), Atovaquone (DRUG), Sulfamethoxazole-Trimethoprim (DRUG).
Who is sponsoring clinical trial NCT00000811?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000811's enrollment target sits among peer trials
690 46th of 2000 higher than 1,954 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults